Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Suzetrigine · Journavx, VX-548

Small molecule · Inhibitor of Nav1.8 voltage-gated sodium channel (SCN10A) · developed by Vertex Pharms

Approved FDA, Jan 2025

VRTX Developer

1 Registered trials

What is Suzetrigine?

Suzetrigine is a selective inhibitor of the Nav1.8 voltage-gated sodium channel expressed in peripheral sensory neurons. By blocking Nav1.8 channels, it inhibits transmission of pain signals to the spinal cord and brain.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Journavx, VX-548, VRT-1737548, VXC-548, JOURNAVX
Drug type: Small molecule
Targets: Nav1.8 voltage-gated sodium channel (SCN10A)
Mechanism: Inhibitor of Nav1.8 voltage-gated sodium channel (SCN10A)
Pathways: pain signal transmission
Therapy area: Neurology
Developer: Vertex Pharms Inc (VRTX)
FDA status: Approved as Journavx (January 30, 2025), NDA219209 · FDA label
UNII: LOG73M21H5

✅ FDA-approved uses

Moderate to severe acute pain, including postoperative pain

From the indications section of the FDA label (version of Jul 21, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07538570	Phase 4	Pain	Recruiting	VRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pain

More from Vertex Pharms

Deutivacaftor FDA approved Elexacaftor FDA approved Exagamglogene Autotemcel FDA approved Ivacaftor FDA approved Tezacaftor FDA approved Vanzacaftor FDA approved Inaxaplin Phase 2/3 Povetacicept Phase 2/3 VX-017 Phase 3 VX-118 Phase 1 VX-264 Phase 1/2 VX-272 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the VRTX page.

Follow VRTX, the company behind Suzetrigine

See VRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VRTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z